ASH — Ashland Inc.

Summary of Ashland's Q2 2026 Earnings Call

1. Key Financial Results and Metrics:

• Sales: $482 million, up 1% year-over-year.
• Adjusted EBITDA: $98 million, down 9% year-over-year; adjusted EBITDA margin at 20%, down 220 basis points.
• Adjusted EPS: $0.91, down 8% year-over-year.
• Operating Cash Flow: $50 million, significantly up from $9 million in the prior year, driven by working capital management.
• Free Cash Flow: $29 million, with a strong liquidity position of approximately $939 million and net debt of just over $1 billion (net leverage of 2.7x).

2. Strategic Updates and Business Highlights:

• Life Sciences: Steady performance with growth in injectables and high-purity excipients; flat sales of $172 million year-over-year.
• Personal Care: Sales increased by 3% year-over-year to $150 million, driven by strong demand for biofunctional actives and microbial protection.
• Specialty Additives: Sales flat year-over-year at $134 million, with mixed demand across end markets; coatings volumes grew while construction sales declined.
• Intermediates: Sales down 5% year-over-year to $35 million, impacted by the Calvert City outage.
• Innovation and Globalization: Strong momentum with new product introductions exceeding full-year targets after just two quarters.

3. Forward Guidance and Outlook:

• Updated Fiscal 2026 Guidance: Sales expected between $1.835 billion to $1.87 billion; adjusted EBITDA forecasted at $385 million to $400 million.
• Adjusted EPS Growth: Anticipated mid-single to high single-digit growth.
• Free Cash Flow Conversion: Expected to be approximately 50% of adjusted EBITDA.
• Market Expectations: Resilient demand in Life Sciences and Personal Care; Specialty Additives and Intermediates expected to remain stable at trough levels.

4. Bad News, Challenges, or Points of Concern:

• Operational Challenges: Ongoing issues at the Hopewell facility affecting productivity; Calvert City outage previously impacted results.
• Pricing Pressure: Modest pricing declines observed, primarily due to carryover impacts from prior pricing actions.
• Market Uncertainty: Concerns regarding energy-related demand due to geopolitical tensions in the Middle East and delays in EV projects affecting intermediates.
• Mixed Demand Environment: Specialty Additives facing challenges with construction sales and regional demand variability.

5. Notable Q&A Insights:

• Pricing Dynamics: Executives emphasized ongoing pricing actions to recover costs, with expectations for gradual realization in the second half of the year.
• Life Sciences Demand: Confidence in recovery for non-pharma nutrition, attributed to order timing rather than market deterioration.
• Future Outlook: Executives expressed cautious optimism for 2027, focusing on operational improvements and the potential for market share gains amid competitive pressures.
• Customer Engagement: The importance of maintaining strong customer relationships and adapting to their needs was highlighted, particularly in the context of dual sourcing strategies.

Overall, while Ashland reported stable sales and strong cash flow, operational challenges and market uncertainties present notable risks that the company is actively working to address.